Issue

Vol. 31 No. 8 (2019): Vol 31 Issue 8

Copyright (c) 2019 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

in silico Evaluation of 4-Amino-5-substituted-4H-1,2,4-triazole-3-thiol Derivatives against DNA Gyrase, COX-2 and Cathepsin B

https://doi.org/10.14233/ajchem.2019.21956
V. Anitha Kumari
Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupathi-517502, India
Shaheen Begum
Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupathi-517502, India
K. Bharathi
Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupathi-517502, India

Corresponding Author(s) : V. Anitha Kumari

anithamedchem@gmail.com

Asian Journal of Chemistry, Vol. 31 No. 8 (2019): Vol 31 Issue 8

Abstract

Biological activities of 1,2,4-triazoles, in particular, anticancer, anti-inflammatory and antimicrobial activities are potentiated by the presence of thiol group and free amino groups. Enticed by this, a series of 1,2,4-triazole derivatives were designed by introducing different substituent groups at 5th position of 4-amino-4H-1,2,4-triazole-3-thiol ring and their binding affinities were determined by molecular docking studies with the targets associated with bacterial infections, inflammation and cancer (DNA gyrase, cyclooxygenase-II (COX-2) and cathepsin B; PBD IDs: 1KZN, 3LN1 and 1SP4). Results revealed that all the compounds displayed good binding affinity towards the selected targets. The designed compounds showed relatively good affinity for cathepsin B and DNA gyrase enzymes when compared to COX-2. In comparison to aromatic groups, substitution with long aliphatic chains at 5th position significantly improved the binding properties of the compounds towards the targets. 1,2,4-Triazole ring was found to be crucial to form hydrogen bonding interactions with the active site amino acid residues. Stearyl and oleayl substituted derivatives (B6 and B7) exhibited superior binding properties and thus disclosing their pharmacological significance. Interestingly none of the compound showed affinity for permeability glycoprotein (P-gp), suggesting that their cellular uptake will be good in cancer cells.

Keywords

1,2,4-Triazoles Molecular docking Cathepsin B Cyclooxygenase-II DNA gyrase subunit B
Kumari, V. A., Begum, S., & Bharathi, K. (2019). in silico Evaluation of 4-Amino-5-substituted-4H-1,2,4-triazole-3-thiol Derivatives against DNA Gyrase, COX-2 and Cathepsin B. Asian Journal of Chemistry, 31(8), 1748–1754. https://doi.org/10.14233/ajchem.2019.21956
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. H.-Z. Zhang, G.L.V. Damu, G.-X. Cai and C.-H. Zhou, Curr. Org. Chem., 18, 359 (2014); https://doi.org/10.2174/13852728113179990025.
  2. A.H. Malani, A.H. Makwana and H.R. Makwana, Moroccan J. Chem., 5, 41 (2017).
  3. S.C. Holm and B.F. Straub, Org. Prep. Proc. Int., 43, 319 (2011); https://doi.org/10.1080/00304948.2011.593999.
  4. S. Maddila, R. Pagadala and S.B. Jonnalagadda, Lett. Org. Chem., 10, 693 (2013); https://doi.org/10.2174/157017861010131126115448.
  5. B.T. Yin, C.Y. Yan, X.M. Peng, S.L. Zhang, S. Rasheed, R.X. Geng and C. Zhou, Eur. J. Med. Chem., 71, 148 (2014); https://doi.org/10.1016/j.ejmech.2013.11.003.
  6. R. Kharb, P.C. Sharma and M.S. Yar, J. Enzyme Inhib. Med. Chem., 26, 1 (2011); https://doi.org/10.3109/14756360903524304.
  7. H.A.M. El-Sherief, B.G.M. Youssif, S.N.A. Bukhari, A.H. Abdelazeem, M.A. Aziz and H.M.A. Rahman, Eur. J. Med. Chem., 156, 774 (2018); https://doi.org/10.1016/j.ejmech.2018.07.024.
  8. N. Raghav and M. Singh, Eur. J. Med. Chem., 77, 231 (2014); https://doi.org/10.1016/j.ejmech.2014.03.007.
  9. K.S. Bhat, B. Poojary, D.J. Prasad, P. Naik and B.S. Holla, Eur. J. Med. Chem., 44, 5066 (2009); https://doi.org/10.1016/j.ejmech.2009.09.010.
  10. D.A. Al-Turki, M.A. Al-Omar, L.A. Abou-zeid, I.A. Shehata and M.S. Al-Awady, Saudi Pharm. J., 25, 59 (2017); https://doi.org/10.1016/j.jsps.2015.07.001.
  11. L. Labanauskas, E. Udrenaite, P. Gaidelis and A. Brukstus, IL Farmaco, 59, 255 (2004); https://doi.org/10.1016/j.farmac.2003.11.002.
  12. S. Pattan, P. Gadhave, V. Tambe, S. Dengale, D. Thakur, S.V. Hiremath, R.V. Shete and P. Deotarse, Indian J. Chem., 51B, 297 (2012).
  13. N. Muthal, J. Ahirwar, D. Ahriwar, P. Masih, T. Mahmdapure and T. Siva Kumar, Int. J. Pharm. Technol. Res., 2, 2450 (2010).
  14. P. Valentina, K. Ilango, M. Deepthi, P. Harusha, G. Pavani, K.L. Sindhura and G. Keerthanan, J. Pharm. Sci. Res., 2, 74 (2009).
  15. O. Demirkol, C. Adams and N. Ercal, J. Agric. Food Chem., 52, 8151 (2004); https://doi.org/10.1021/jf040266f.
  16. C.A. Lipinski, F. Lombardo, B.W. Dominy and P.J. Feeney, Adv. Drug Deliv. Rev., 46, 3 (2001); https://doi.org/10.1016/S0169-409X(00)00129-0.
  17. C.A. Lipinski, Drug Discov. Today. Technol., 1, 337 (2004); https://doi.org/10.1016/j.ddtec.2004.11.007.
  18. P. Ertl, B. Rohde and P. Selzer, J. Med. Chem., 43, 3714 (2000); https://doi.org/10.1021/jm000942e.
  19. U. Haberthur and A. Caflisch, J. Comput. Chem., 29, 701 (2008); https://doi.org/10.1002/jcc.20832.
  20. A.K. Ghose, V.N. Viswanadhan and J.J. Wendoloski, J. Comb. Chem., 1, 55 (1999); https://doi.org/10.1021/cc9800071.
  21. D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward and K.D. Kopple, J. Med. Chem., 45, 2615 (2002); https://doi.org/10.1021/jm020017n.
  22. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng and T.E. Ferrin, J. Comput. Chem., 13, 1605 (2004); https://doi.org/10.1002/jcc.20084.
  23. D.G. Gfeller, A. Grosdidier, M. Wirth, A. Diana, M. Olivier and V. Zoete, Nucleic Acids Res., 42, W32 (2014); https://doi.org/10.1093/nar/gku293.
  24. A. Grosdidier, V. Zoete and O. Michielin, Protein, 67, 1010 (2007); https://doi.org/10.1002/prot.21367.
  25. A. Grosdidier, V. Zoete and O. Michielin, Nucleic Acids Res., 39(suppl), W270 (2011); https://doi.org/10.1093/nar/gkr366.
  26. B. Arifa, B. Shaheen, K. Prasad and K. Bharathi, Int. J. Pharm. Pharm. Sci., 9, 209 (2017); https://doi.org/10.22159/ijpps.2017v9i8.19835.
  27. D.S. Miller, Trends Pharmacol. Sci., 31, 246 (2010); https://doi.org/10.1016/j.tips.2010.03.003.
  28. F. Li, X. Zhou, H. Zhou, J. Jia, L. Li, S. Zhai and B. Yan. B, PLoS One, 11, e0160042 (2016); https://doi.org/10.1371/journal.pone.0160042.
  29. M.A. Ismail, S. Al-Shihry, R.K. Arafa and U. El-Ayaan, J. Enzyme Inhib. Med. Chem., 28, 530 (2013); https://doi.org/10.3109/14756366.2011.654113.
  30. R. Jarapula, K. Gangarapu, S. Manda and S. Rekulapally, Int. J. Med. Chem., 2016, Article ID 2181027 (2016); https://doi.org/10.1155/2016/2181027.
  31. N.P. Withania, G. Blum, M. Sameni, C. Slaney, A. Anbalagan and B. Mary Olive, Clin. Cancer Res., (2012).
  32. J. Kos, A. Mitroviæ and B. Mirkoviæ, Future Med. Chem., 6, 1355 (2014); https://doi.org/10.4155/fmc.14.73.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0